Now Available: Spotlight on Fluent BioSciences CEO Brian McKernan. Click here to read.
DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand, today announced it has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management. The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform.
Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management and improve patient outcomes, today announced it has signed a definitive agreement to acquire Cernostics, Inc. (Cernostics), an Illumina Ventures company. Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies. Its TissueCypher® ...
RedShift BioAnalytics Inc. (RedShiftBioⓇ), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, announced today the closing of its Series E Preferred Stock financing. The $20 million financing was led by Illumina Ventures and joined by all of the company’s current major investors, including Technology Venture ...
National Venture Capital Association interviews Nick Naclerio, Founding Partner at Illumina Ventures, to learn more about the firm... Illumina Ventures invests in early-stage life science companies with a particular focus on genomics and precision health. Our team and our unique relationship with Illumina, Inc. (NASDAQ: ILMN) is what sets us apart from other firms. Our members have been both ...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
